Hypertrophic cardiomyopathy (HCM) is classified as non-obstructive or obstructive, based on the presence of left ventricular outflow tract (LVOT) obstruction. The threshold for obstructive HCM is ≥ 30 mmHg whereas a gradient ≥ 50 mmHg is generally regarded as the threshold for clinically significant obstruction a...
E. Barba, P. Zwetsloot, A. Hirsch et al.· European Heart Journal· 0 citations
Elderly patients constitute a growing proportion of patients with heart failure with reduced ejection fraction (HFrEF), yet remain underrepresented in randomized clinical trials shaping treatment recommendations. We evaluated age-related differences in real-world contemporary HFrEF care.
TITRATE-HF is a pr...
J. J. N. Krabbe, M. I. Wilde, W. L. Verloop et al.· European Heart Journal· 0 citations
Elevated levels of cardiorenal-inflammatory markers reflect not only risk of cardiovascular disease (CVD), but also of cancer. The objectives of the current study were to examine whether N-terminal pro-B-type natriuretic peptide (NT-proBNP), urinary albumin excretion (UAE) and high-sensitivity C reactive protein...
Y. Yang, T.-F. Kok, M. Maronier et al.· European Heart Journal· 0 citations
Abstract Background Obesity is strongly associated with heart failure (HF), but recognition remains challenging in primary care because symptoms, physical findings, and natriuretic peptide concentrations may be difficult to interpret. Objectives To describe the design, recruitment, baseline characteristics, and accepta...
P. A. Motiram, Jie-Fen Chin, E. Rouwet et al.· ESC Heart Failure· 0 citations
OBJECTIVES
During venoarterial extracorporeal membrane oxygenation (VA ECMO), organ perfusion no longer entirely depends on native cardiac output, which may reduce the therapeutic advantage of inotropic drugs relative to their risks. We hypothesized that, in this setting, higher cumulative inotropic exposure would be a...
M. V. van Steenwijk, L. Pladet, Atreyu van Esch et al.· Critical Care Medicine· 0 citations
This review paper aims to provide a structured and evidence-informed framework to guide personalized management of DCM and NDLVC, starting from the phenotype towards precision medicine.
R. D. de Boer, A. Chaloupka, Bethan Cowley et al.· European Journal of Heart Fa...· 0 citations
It is hypothesized that severity of established CTRCD in this subgroup might be too advanced for significant LVEF improvements, and statins hold promise in the prevention of anthracycline- and/or anti-HER2-mediated CTRCD, whereas no beneficial effect was observed in patients with combination regimens.
Y. Appels, R. Parvan, C. G. Mohan et al.· European Heart Journal, Supp...· 0 citations
The findings underscore the need for implementation and dosing strategies that account for differences between men and women regarding GDMT implementation, side effects, change in left ventricular ejection fraction (LVEF), and clinical outcomes.
M. I. Wilde, J. J. N. Krabbe, L. J. Bouhuijzen et al.· European Heart Journal - Qua...· 0 citations
The manifold of CVD and CV health indicators increase the risk of new-onset cancer and cancer-related mortality, and the need for awareness of future cancer in patients with CVD is emphasized.
L. Yousif, P. Ameri, M. Vinci et al.· European Heart Journal, Supp...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
